TEHRAN (Dispatches) -- The medicine for patients with Amyotrophic Lateral Sclerosis (ALS) was unveiled on Sunday in the presence of Iran’s Vice President for Science and Technology.
The drug is in the form of Edaravone injection vials by a knowledge-based company in the Growth Center of Iran University of Medical Sciences (IUMS).
The ALS medicine has hit the domestic consumer market and about 50 patients have used it.
ALS disease causes destruction of mobile cells in the spinal cord and is considered as a type of degenerative disease.
Statistics showed that 10 and 90 percent of patients with ALS have either been genetically or diagnosed with the disease respectively.
According to neurologists, the ALS disease is a degenerative disease that cannot be cured.
Iran has been cutting reliance on medical imports by developing its own pharmaceutical industry.